para-Fluorophenylpiperazine

From Self-sufficiency
Jump to: navigation, search
Para-Fluorophenylpiperazine
150px
150px
Systematic (IUPAC) name
1-(4-fluorophenyl)piperazine
Clinical data
Routes of
administration
Oral
Legal status
Legal status
  • Class C (New Zealand)
Pharmacokinetic data
Metabolism Hepatic
Biological half-life 6-8 hours
Excretion Renal
Identifiers
CAS Number 64090-19-3 2252-63-3, 64090-19-3
PubChem CID 75260
Chemical data
Formula C10H13FN2
Molar mass 180.222 g/mol[[Script error: No such module "String".]]
Script error: No such module "TemplatePar".Expression error: Unexpected < operator.

para-Fluorophenylpiperazine (pFPP, 4-FPP; Fluoperazine, Flipiperazine) is a piperazine derivative with mildly psychedelic and euphoriant effects.[1][2] It has been sold as an ingredient in legal recreational drugs known as "Party pills", initially in New Zealand and subsequently in other countries around the world.

pFPP has been found in vitro to act mainly as a 5-HT1A receptor agonist, with some additionally affinity for the 5-HT2A and 5-HT2C receptors. It has also been shown to inhibit the reuptake of serotonin and norepinephrine, and to possibly induce their release.

pFPP was originally discovered as a metabolite of the hypnotic antihistamine niaprazine in 1982,[3] but was rediscovered in 2003 as a potential recreational drug, and sold as an ingredient in "Party pills" in New Zealand, under brand names such as "The Big Grin", "Mashed", and "Extreme Beans". Subsequently it has continued to be used as an ingredient in black market "ecstasy" pills around the world.[4]

pFPP has little stimulant effects, with its subjective effects derived mainly from its action as a 5-HT1A receptor agonist.[5] pFPP is active at doses between 20–150 mg, but higher doses cause a range of side effects such as migraine headaches, muscle aches, anxiety, nausea, and vomiting.

Based on the recommendation of the EACD, the New Zealand government has passed legislation which placed BZP, along with a number of other piperazine derivatives into Class C of the New Zealand Misuse of Drugs Act 1975. A ban was intended to come into effect in New Zealand on December 18 2007, but the law change did not go through until the following year, and the sale of BZP and the other listed piperazines became illegal in New Zealand as of 1st of April 2008. An amnesty for possession and usage of these drugs remained until October 2008, at which point they became completely illegal.[6]

See also

References

Cite error: Invalid <references> tag; parameter "group" is allowed only.

Use <references />, or <references group="..." />
  1. Erowid Experience Vaults: Piperazines - pFPP - Refreshing Enhancement - 62575
  2. Erowid Experience Vaults: Piperazines - pFPP - A Little Flip'd Out - 56641
  3. Keane PE, Strolin Benedetti M, Dow J. The effect of niaprazine on the turnover of 5-hydroxytryptamine in the rat brain. Neuropharmacology. 1982 Feb;21(2):163-9.
  4. DEA Microgram Bulletin August 2009
  5. Scherman D, Hamon M, Gozlan H, Henry JP, Lesage A, Masson M, Rumigny JF. Molecular pharmacology of niaprazine. Progress in Neuro-psychopharmacology and Biological Psychiatry. 1988;12(6):989-1001.
  6. Misuse of Drugs (Classification of BZP) Amendment Bill 2008